In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tom Salemi

Advertisement
Set Alert for Articles By Tom Salemi

Latest From Tom Salemi

Glaukos Holds Lead In Microinvasive Glaucoma Surgery

Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.

Medical Device

Finding The Fit For Ophthalmology In The New Pfizer

The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.

BioPharmaceutical Medical Device

New Enterprise Flies Higher

New Enterprise Associates surprised some by locking down $3.1 billion in new capital during a tight fundraising climate. General partner David Mott and partner Justin Klein share the firm’s investment approach.

BioPharmaceutical Medical Device

New NEA Fund Could Bring $1 Billion To Health Care

Following two years of strong exits from biopharma and medtech investment, New Enterprise Associates raised over $3.1 billion for its 15th fund raising. The new pool of capital consists of $2.8 billion for a traditional venture fund – the fourth consecutive fund to top $2.5 billion – and a $350 million “Opportunity Fund” that will be co-invested with the new and prior fund in late-stage growth equity deals.

BioPharmaceutical Medical Device

Timing, Returns Record Right For Vivo Capital Fundraising

Once a lesser known firm in US life sciences investing, Vivo Capital has emerged as a global leader in biopharmaceutical and medtech start-ups, raising a $750 million fund that will be invested in the US, Europe, and China.

Medical Device BioPharmaceutical

The Making Of A CEO: Robert Greenberg, MD

Robert Greenberg, MD, hadn’t served as a CEO prior to taking the post at Second Sight, didn’t even post any significant executive experience. But he did have some success as an entrepreneur prior to joining the company.

Medical Device
See All
Advertisement
UsernamePublicRestriction

Register